Drug Profile
Research programme: norovirus and rotavirus vaccine - University of Tampere/UMN Pharma
Latest Information Update: 08 Mar 2023
Price :
$50
*
At a glance
- Originator University of Tampere Vaccine Research Center
- Developer UMN Pharma; University of Tampere Vaccine Research Center
- Class Viral vaccines; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Gastroenteritis; Norovirus infections; Rotavirus infections
Most Recent Events
- 08 Mar 2023 Preclinical development is ongoing in Norovirus-infections(Prevention) in Japan (Parenteral, Injection) (UMN Pharma pipeline, February 2023 )
- 08 Mar 2023 Preclinical development is ongoing in Rotavirus-infections(In children, Prevention) in Finland (Parenteral, Injection) (UMN Pharma pipeline, February 2023)
- 08 Mar 2023 Preclinical development is ongoing in Gastroenteritis(In children, Prevention) in Finland (Parenteral, Injection) (UMN Pharma pipeline, February 2023)